OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma
Lin Chen, Siyuan Liu, Dickson Adah, et al.
Immunology (2023) Vol. 169, Iss. 2, pp. 204-218
Open Access | Times Cited: 13
Lin Chen, Siyuan Liu, Dickson Adah, et al.
Immunology (2023) Vol. 169, Iss. 2, pp. 204-218
Open Access | Times Cited: 13
Showing 13 citing articles:
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
Alexandre V. Hirayama, Erik L. Kimble, Jocelyn H. Wright, et al.
Blood Advances (2023) Vol. 8, Iss. 2, pp. 453-467
Open Access | Times Cited: 17
Alexandre V. Hirayama, Erik L. Kimble, Jocelyn H. Wright, et al.
Blood Advances (2023) Vol. 8, Iss. 2, pp. 453-467
Open Access | Times Cited: 17
CAR-T cell combination therapies in hematologic malignancies
Delian Zhou, Xiaojian Zhu, Yi Xiao
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Delian Zhou, Xiaojian Zhu, Yi Xiao
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 7
Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments
Xudong Li, Wei Li, Linping Xu, et al.
Chinese Medical Journal (2023) Vol. 137, Iss. 11, pp. 1285-1302
Open Access | Times Cited: 13
Xudong Li, Wei Li, Linping Xu, et al.
Chinese Medical Journal (2023) Vol. 137, Iss. 11, pp. 1285-1302
Open Access | Times Cited: 13
CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside
Xingwang Zhu, Jianxin Xue, Haifeng Jiang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Xingwang Zhu, Jianxin Xue, Haifeng Jiang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 4
Unlocking the potential of chimeric antigen receptor T cell engineering immunotherapy: Long road to achieve precise targeted therapy for hepatobiliary pancreatic cancers
Hongli Gao, Lianyue Qu, Mu Li, et al.
International Journal of Biological Macromolecules (2025) Vol. 297, pp. 139829-139829
Closed Access
Hongli Gao, Lianyue Qu, Mu Li, et al.
International Journal of Biological Macromolecules (2025) Vol. 297, pp. 139829-139829
Closed Access
Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression
Mingzhen Zhou, Ziyan Zhou, Lina Hu, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Mingzhen Zhou, Ziyan Zhou, Lina Hu, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Pei Guo, Liyuan Zhong, Tao Wang, et al.
Scandinavian Journal of Immunology (2025) Vol. 101, Iss. 2
Closed Access
The progress of natural killer cells in the treatment of immune response to hepatocellular carcinoma
New medicine. (2025), pp. 1-7
Closed Access
New medicine. (2025), pp. 1-7
Closed Access
Hepatocellular Carcinoma and the Multifaceted Relationship with Its Microenvironment: Attacking the Hepatocellular Carcinoma Defensive Fortress
Linda Galasso, Lucia Cerrito, Valeria Maccauro, et al.
Cancers (2024) Vol. 16, Iss. 10, pp. 1837-1837
Open Access | Times Cited: 2
Linda Galasso, Lucia Cerrito, Valeria Maccauro, et al.
Cancers (2024) Vol. 16, Iss. 10, pp. 1837-1837
Open Access | Times Cited: 2
Ubiquitin-proteasome system-based signature to predict the prognosis and drug sensitivity of hepatocellular carcinoma
Jianxiang Zhang, Liwen Liu, Zenghan Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Jianxiang Zhang, Liwen Liu, Zenghan Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
Yan Wang, Shengjie Jin, Qiqi Zhuang, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 6
Yan Wang, Shengjie Jin, Qiqi Zhuang, et al.
MedComm (2023) Vol. 4, Iss. 6
Open Access | Times Cited: 6
Recent advances and progress in immunotherapy of solid cancers
Amit Kumar, Luni Emdad, Swadesh K. Das, et al.
Advances in cancer research (2024), pp. 111-190
Closed Access | Times Cited: 1
Amit Kumar, Luni Emdad, Swadesh K. Das, et al.
Advances in cancer research (2024), pp. 111-190
Closed Access | Times Cited: 1
Role of immunotherapies and stem cell therapy in the management of liver cancer: A comprehensive review
Fares E.M. Ali, Islam M. Ibrahim, Hanan S. Althagafy, et al.
International Immunopharmacology (2024) Vol. 132, pp. 112011-112011
Closed Access
Fares E.M. Ali, Islam M. Ibrahim, Hanan S. Althagafy, et al.
International Immunopharmacology (2024) Vol. 132, pp. 112011-112011
Closed Access
